These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 38245601)
1. Real-world analysis of teclistamab in 123 RRMM patients from Germany. Riedhammer C; Bassermann F; Besemer B; Bewarder M; Brunner F; Carpinteiro A; Einsele H; Faltin J; Frenking J; Gezer D; Goldman-Mazur S; Hänel M; Hoegner M; Kortuem KM; Krönke J; Kull M; Leitner T; Mann C; Mecklenbrauck R; Merz M; Morgner A; Nogai A; Raab MS; Teipel R; Wäsch R; Rasche L Leukemia; 2024 Feb; 38(2):365-371. PubMed ID: 38245601 [TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience. Dima D; Davis JA; Ahmed N; Jia X; Sannareddy A; Shaikh H; Shune L; Kaur G; Khouri J; Afrough A; Strouse C; Lochner J; Mahmoudjafari Z; Raza S; Valent J; Anderson LD; Anwer F; Abdallah AO; Hashmi H Transplant Cell Ther; 2024 Mar; 30(3):308.e1-308.e13. PubMed ID: 38151105 [TBL] [Abstract][Full Text] [Related]
3. Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study. Caillot L; Sleiman E; Lafon I; Chretien ML; Gueneau P; Payssot A; Pedri R; Lakomy D; Bailly F; Guy J; Quenot JP; Avet-Loiseau H; Caillot D Transplant Cell Ther; 2024 Jun; 30(6):630.e1-630.e8. PubMed ID: 38458477 [TBL] [Abstract][Full Text] [Related]
4. Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients. Sanoyan DA; Seipel K; Bacher U; Kronig MN; Porret N; Wiedemann G; Daskalakis M; Pabst T BMC Cancer; 2023 Apr; 23(1):345. PubMed ID: 37061680 [TBL] [Abstract][Full Text] [Related]
5. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396 [TBL] [Abstract][Full Text] [Related]
6. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. Anderson LD Future Oncol; 2022 Jan; 18(3):277-289. PubMed ID: 34854741 [TBL] [Abstract][Full Text] [Related]
7. Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma. Minakata D; Ishida T; Ando K; Suzuki R; Tanaka J; Hagiwara S; Ananthakrishnan R; Kuwayama S; Nishio M; Kanda Y; Suzuki K Int J Hematol; 2023 May; 117(5):729-737. PubMed ID: 36690910 [TBL] [Abstract][Full Text] [Related]
8. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. Hansen DK; Sidana S; Peres LC; Colin Leitzinger C; Shune L; Shrewsbury A; Gonzalez R; Sborov DW; Wagner C; Dima D; Hashmi H; Kocoglu MH; Atrash S; Simmons G; Kalariya N; Ferreri C; Afrough A; Kansagra A; Voorhees P; Baz R; Khouri J; Alsina M; McGuirk J; Locke FL; Patel KK J Clin Oncol; 2023 Apr; 41(11):2087-2097. PubMed ID: 36623248 [TBL] [Abstract][Full Text] [Related]
9. Teclistamab in Relapsed or Refractory Multiple Myeloma. Moreau P; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Nooka AK; Martin T; Rosinol L; Chari A; Karlin L; Benboubker L; Mateos MV; Bahlis N; Popat R; Besemer B; Martínez-López J; Sidana S; Delforge M; Pei L; Trancucci D; Verona R; Girgis S; Lin SXW; Olyslager Y; Jaffe M; Uhlar C; Stephenson T; Van Rampelbergh R; Banerjee A; Goldberg JD; Kobos R; Krishnan A; Usmani SZ N Engl J Med; 2022 Aug; 387(6):495-505. PubMed ID: 35661166 [TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Anderson LD; Dhakal B; Jain T; Oluwole OO; Shah GL; Sidana S; Perales MA; Pasquini MC Transplant Cell Ther; 2024 Jan; 30(1):17-37. PubMed ID: 37913909 [TBL] [Abstract][Full Text] [Related]
11. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Jagannath S; Lin Y; Goldschmidt H; Reece D; Nooka A; Senin A; Rodriguez-Otero P; Powles R; Matsue K; Shah N; Anderson LD; Streetly M; Wilson K; Le HV; Swern AS; Agarwal A; Siegel DS Blood Cancer J; 2021 Jun; 11(6):116. PubMed ID: 34145225 [TBL] [Abstract][Full Text] [Related]
12. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma. Lee DH; Kumar A; Mohammed T; Peres LC; Alsina M; Bachmeier C; Blue BJ; Brayer J; Chandrasekhar S; Grajales Cruz A; De Avila G; Elmariah H; Faramand R; Freeman C; Jain M; Khadka S; Khimani F; Liu H; Nishihori T; Oswald LB; Castaneda Puglianini OA; Shain KH; Smith E; Baz RC; Locke FL; Oliveira GH; Alomar M; Hansen DK Blood Adv; 2023 Aug; 7(16):4247-4257. PubMed ID: 37307173 [TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma. Moreau P; van de Donk NWCJ; Delforge M; Einsele H; De Stefano V; Perrot A; Besemer B; Pawlyn C; Karlin L; Manier S; Leleu X; Weisel K; Ghilotti F; Diels J; Elsada A; Morano R; Strulev V; Pei L; Kobos R; Smit J; Slavcev M; Mateos MV Adv Ther; 2023 May; 40(5):2412-2425. PubMed ID: 36961654 [TBL] [Abstract][Full Text] [Related]
14. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Mohan M; Monge J; Shah N; Luan D; Forsberg M; Bhatlapenumarthi V; Balev M; Patwari A; Cheruvalath H; Bhutani D; Thanendrarajan S; Dhakal B; Zangari M; Al-Hadidi S; Cooper D; Lentzsch S; van Rhee F; D'Souza A; Szabo A; Schinke C; Chakraborty R Blood Cancer J; 2024 Mar; 14(1):35. PubMed ID: 38443345 [TBL] [Abstract][Full Text] [Related]
15. Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple Myeloma. Martin T; Jackson CC; Pacaud L; Madduri D; Jagannath S Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):22-27. PubMed ID: 36411210 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study. Dima D; Rashid A; Davis JA; Shune L; Abdallah AO; Li H; DeJarnette S; Khouri J; Williams L; Hashmi H; Raza S; McGuirk J; Anwer F; Ahmed N Br J Haematol; 2024 Apr; 204(4):1293-1299. PubMed ID: 38263627 [TBL] [Abstract][Full Text] [Related]
17. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. Rodriguez-Otero P; Ailawadhi S; Arnulf B; Patel K; Cavo M; Nooka AK; Manier S; Callander N; Costa LJ; Vij R; Bahlis NJ; Moreau P; Solomon SR; Delforge M; Berdeja J; Truppel-Hartmann A; Yang Z; Favre-Kontula L; Wu F; Piasecki J; Cook M; Giralt S N Engl J Med; 2023 Mar; 388(11):1002-1014. PubMed ID: 36762851 [TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1. Miao X; Wu LS; Lin SXW; Xu Y; Chen Y; Iwaki Y; Kobos R; Stephenson T; Kemmerer K; Uhlar CM; Banerjee A; Goldberg JD; Trancucci D; Apte A; Verona R; Pei L; Desai R; Hickey K; Su Y; Ouellet D; Samtani MN; Guo Y; Garfall AL; Krishnan A; Usmani SZ; Zhou H; Girgis S Target Oncol; 2023 Sep; 18(5):667-684. PubMed ID: 37713090 [TBL] [Abstract][Full Text] [Related]
19. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. Zanwar S; Sidana S; Shune L; Puglianini OC; Pasvolsky O; Gonzalez R; Dima D; Afrough A; Kaur G; Davis JA; Herr M; Hashmi H; Forsberg P; Sborov D; Anderson LD; McGuirk JP; Wagner C; Lieberman-Cribbin A; Rossi A; Freeman CL; Locke FL; Richard S; Khouri J; Lin Y; Patel KK; Kumar SK; Hansen DK J Hematol Oncol; 2024 Jun; 17(1):42. PubMed ID: 38845015 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies. Touzeau C; Krishnan AY; Moreau P; Perrot A; Usmani SZ; Manier S; Cavo M; Martinez Chamorro C; Nooka AK; Martin TG; Karlin L; Leleu X; Bahlis NJ; Besemer B; Pei L; Stein S; Wang Lin SX; Trancucci D; Verona R; Girgis S; Miao X; Uhlar C; Chastain K; Garfall A Blood; 2024 Aug; ():. PubMed ID: 39172760 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]